Total Payments
$3.4M
2024 Payments
$435,243
Companies
54
Transactions
4,310
Medicare Patients
11,007
Medicare Billing
$1.9M
Payment Breakdown by Category
Other$2.7M (79.1%)
Travel$440,911 (12.9%)
Consulting$145,171 (4.2%)
Food & Beverage$95,914 (2.8%)
Research$35,337 (1.0%)
Education$902.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.5M | 837 | 73.2% |
| Travel and Lodging | $440,911 | 1,104 | 12.9% |
| Consulting Fee | $145,171 | 62 | 4.2% |
| Honoraria | $136,681 | 30 | 4.0% |
| Food and Beverage | $95,914 | 2,205 | 2.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $65,720 | 17 | 1.9% |
| Unspecified | $35,337 | 32 | 1.0% |
| Education | $902.92 | 23 | 0.0% |
Payments by Type
General
$3.4M
4,278 transactions
Research
$35,337
32 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $818,189 | 948 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $523,174 | 374 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $441,494 | 507 | $0 (2024) |
| GENZYME CORPORATION | $217,493 | 225 | $0 (2023) |
| Lilly USA, LLC | $177,462 | 281 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $169,837 | 158 | $0 (2024) |
| Janssen Biotech, Inc. | $153,126 | 246 | $0 (2024) |
| Amgen Inc. | $144,437 | 192 | $0 (2024) |
| Celgene Corporation | $142,590 | 186 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $100,972 | 209 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $435,243 | 559 | ABBVIE INC. ($122,895) |
| 2023 | $438,340 | 571 | AbbVie Inc. ($149,394) |
| 2022 | $407,490 | 519 | ABBVIE INC. ($148,466) |
| 2021 | $383,972 | 448 | AbbVie Inc. ($108,170) |
| 2020 | $161,366 | 223 | Janssen Scientific Affairs, LLC ($38,193) |
| 2019 | $506,035 | 613 | Janssen Scientific Affairs, LLC ($96,382) |
| 2018 | $600,358 | 739 | Regeneron Healthcare Solutions, Inc. ($118,761) |
| 2017 | $496,663 | 638 | Janssen Scientific Affairs, LLC ($118,819) |
All Payment Transactions
4,310 individual payment records from CMS Open Payments — Page 1 of 173
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $112.08 | General |
| 12/18/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $27.49 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug), DUOBRII, TARGRETIN | Food and Beverage | In-kind items and services | $19.81 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,697.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/14/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $1,423.50 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/14/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $1,138.80 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $244.90 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $123.25 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.28 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/11/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $19.48 | General |
| Category: Dermatology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: Immunology | ||||||
| 12/11/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $2.09 | General |
| Category: Dermatology | ||||||
| 12/10/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $119.37 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 12/09/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $22.03 | General |
| Category: Dermatology | ||||||
| 12/09/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $7.57 | General |
| Category: Immunology | ||||||
| 12/09/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $5.29 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $137.51 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $33.67 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $21.95 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $30.74 | General |
| Category: Inflammation | ||||||
| 12/04/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $8.57 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/03/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $24.14 | General |
| Category: DERMATOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $19,654 | 5 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $5,964 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $2,073 | 4 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | Eli Lilly and Company | $1,531 | 3 |
| CC-10004-PSOR-008 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis | Celgene Corporation | $1,524 | 1 |
| A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $1,377 | 2 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | Eli Lilly and Company | $1,099 | 1 |
| A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 | Eli Lilly and Company | $918.73 | 3 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients with Plaque Psoriasis. | Allergan Inc. | $402.22 | 6 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $268.58 | 1 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $249.11 | 1 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $239.24 | 1 |
| A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $37.67 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 2,421 | 7,499 | $1.9M | $557,694 |
| 2022 | 25 | 2,267 | 6,685 | $1.7M | $498,717 |
| 2021 | 27 | 2,597 | 7,738 | $1.7M | $552,279 |
| 2020 | 28 | 3,722 | 6,413 | $893,888 | $263,904 |
Total Patients
11,007
Total Services
28,335
Medicare Billing
$1.9M
Procedure Codes
105
All Medicare Procedures & Services
105 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3245 | Injection, tildrakizumab, 1 mg | Office | 2023 | 14 | 3,300 | $1.2M | $362,432 | 31.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 642 | 934 | $199,869 | $53,597 | 26.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 320 | 390 | $91,597 | $24,115 | 26.3% |
| 13132 | Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | Office | 2023 | 51 | 55 | $61,012 | $18,116 | 29.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 333 | 430 | $67,343 | $14,792 | 22.0% |
| 17263 | Destruction of cancer skin growth of trunk, arms, or legs, 2.1-3.0 cm | Office | 2023 | 72 | 100 | $45,241 | $11,288 | 25.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 242 | 285 | $37,906 | $10,643 | 28.1% |
| 14060 | Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | Office | 2023 | 12 | 13 | $23,662 | $7,594 | 32.1% |
| 14040 | Repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet by transferring skin, 10.0 sq cm or less | Office | 2023 | 12 | 12 | $21,497 | $6,913 | 32.2% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 114 | 182 | $21,265 | $6,487 | 30.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 250 | 1,369 | $25,139 | $6,071 | 24.1% |
| 17273 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 2.1-3.0 cm | Office | 2023 | 27 | 32 | $15,721 | $4,497 | 28.6% |
| 13121 | Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | Office | 2023 | 13 | 13 | $12,965 | $3,827 | 29.5% |
| 13101 | Complicated repair of wound of trunk, 2.6-7.5 cm | Office | 2023 | 15 | 15 | $13,978 | $3,799 | 27.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 34 | 41 | $12,435 | $3,677 | 29.6% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 30 | 33 | $12,997 | $3,349 | 25.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 40 | 41 | $10,756 | $3,182 | 29.6% |
| 17283 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 2.1-3.0 cm | Office | 2023 | 16 | 18 | $10,310 | $3,026 | 29.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 42 | 42 | $11,184 | $2,813 | 25.2% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 28 | 29 | $8,457 | $2,527 | 29.9% |
| 17264 | Destruction of cancer skin growth of trunk, arms, or legs, 3.1-4.0 cm | Office | 2023 | 15 | 19 | $9,193 | $2,300 | 25.0% |
| 69100 | Biopsy of ear | Office | 2023 | 19 | 23 | $5,181 | $1,056 | 20.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 56 | 99 | $3,280 | $958.50 | 29.2% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 12 | 12 | $2,041 | $548.00 | 26.9% |
| 86580 | Skin test for tuberculosis | Office | 2023 | 12 | 12 | $269.45 | $86.64 | 32.2% |
About Dr. David Cohen, MD
Dr. David Cohen, MD is a Dermatology healthcare provider based in Macon, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1487652020.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Cohen, MD has received a total of $3.4M in payments from pharmaceutical and medical device companies, with $435,243 received in 2024. These payments were reported across 4,310 transactions from 54 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.5M).
As a Medicare-enrolled provider, Cohen has provided services to 11,007 Medicare beneficiaries, totaling 28,335 services with total Medicare billing of $1.9M. Data is available for 4 years (2020–2023), covering 105 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Macon, GA
- Active Since 07/08/2005
- Last Updated 05/19/2008
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1487652020
Products in Payments
- DUPIXENT (Biological) $315,091
- TREMFYA (Drug) $298,593
- RINVOQ (Biological) $293,239
- Otezla (Drug) $255,685
- SKYRIZI (Biological) $211,180
- Tremfya (Drug) $210,786
- DUPIXENT DUPILUMAB INJECTION (Biological) $187,758
- TALTZ (Drug) $148,338
- Humira (Biological) $131,490
- STELARA (Biological) $113,726
- COSENTYX (Biological) $100,407
- ILUMYA (Biological) $99,192
- VTAMA (Drug) $90,641
- OPZELURA (Drug) $87,690
- DUPIXENT (Drug) $79,746
- SILIQ (Drug) $66,508
- Cimzia (Drug) $52,845
- EUCRISA (Drug) $50,079
- Ilumya (Biological) $47,209
- SIMPONI ARIA (Biological) $44,404
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Macon
David Kent, Md, MD
Dermatology — Payments: $27,255
Dermatology $27,255
Dr. Jennifer Allen, M.d, M.D
Dermatology — Payments: $18,527
Dermatology $18,527
Billie Jackson, M.d, M.D
Dermatology — Payments: $11,501
Dermatology $11,501
Virginia Hall, M.d, M.D
Dermatology — Payments: $9,246
Dermatology $9,246
Bruce Allen, M.d, M.D
Dermatology — Payments: $3,548
Dermatology $3,548
Supriya Immaneni, Md, MD
Dermatology — Payments: $1,667
Dermatology $1,667